Page last updated: 2024-09-04

tipifarnib and fulvestrant

tipifarnib has been researched along with fulvestrant in 1 studies

Compound Research Comparison

Studies
(tipifarnib)
Trials
(tipifarnib)
Recent Studies (post-2010)
(tipifarnib)
Studies
(fulvestrant)
Trials
(fulvestrant)
Recent Studies (post-2010) (fulvestrant)
30992942,7122071,196

Protein Interaction Comparison

ProteinTaxonomytipifarnib (IC50)fulvestrant (IC50)
Estrogen receptorHomo sapiens (human)0.0061
Estrogen receptorRattus norvegicus (Norway rat)0.0059
Progesterone receptorHomo sapiens (human)0.0002
Steroid hormone receptor ERR1Homo sapiens (human)0.002
Bifunctional epoxide hydrolase 2Homo sapiens (human)0.006
Estrogen receptor betaHomo sapiens (human)0.0104
Bile acid receptorHomo sapiens (human)0.79
NAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)2.6

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Christos, PJ; Hershman, DL; Hoschander, S; Li, T; O'Brien, K; Sparano, JA; Vahdat, LT; Wright, JJ1

Trials

1 trial(s) available for tipifarnib and fulvestrant

ArticleYear
Phase II trial of the farnesyltransferase inhibitor tipifarnib plus fulvestrant in hormone receptor-positive metastatic breast cancer: New York Cancer Consortium Trial P6205.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2009, Volume: 20, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Farnesyltranstransferase; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Metastasis; Quinolones; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome

2009